Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Maintenance After EV/P Induction in Front-Line mUC
NCT07221942Phase 2Recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Jan 2026
- Primary completion
- Sep 2028
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, enfortumab vedotin in urothelial carcinoma (UC), sponsored by Fox Chase Cancer Center. Started Jan 2026; status: recruiting.
02
Drugs
pembrolizumabenfortumab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07221942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221942.